How to use the C-reactive protein in cardiac disease?;Come utilizzare la proteina C reattiva nelle patologie cardiache?

Minerva Cardioangiologica

Volumn 53, Issue 1, 2005, Pages 59-68

  Ursella, S ^a   Mazzone, M ^a   Portale, G ^a   Testa, A ^a   Pignataro, G ^a   Covino, M ^a   Fenici, P ^a   Gasbarrini, G B ^a   Silveri, N Gentiloni ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

C reactive protein; Coronary disease; Inflammation; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIOXIDANT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; ESTROGEN; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; ORAL CONTRACEPTIVE AGENT; PRAVASTATIN; TAMOXIFEN; TROPONIN;

ANGINA PECTORIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DEATH; DRUG MECHANISM; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REVIEW; RISK FACTOR; UNSTABLE ANGINA PECTORIS; BLOOD; INFLAMMATION; METABOLISM; PREDICTION AND FORECASTING;

ANGINA, UNSTABLE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; HUMANS; INFLAMMATION; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 16244401070     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-9.
2. Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentraxins) and serum amyloid A protein. Adv Immunol 1983;34:14l-212.
3. Tillett WS, Francis T Jr. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med 1930;52:561-71.
4. Biasucci LM, Liuzzo G, Colizzi C, Rizzello V. Clinical use of C-reactive protein for the prognostic stratification of patients with ischemic heart disease. Ital Heart J 2001;2:164-71.
5. Gabay C, Kushner I. Mechanisms of disease: acute phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54.
6. de Maat MPM, Kluft C. Determinants of C-reactive protein concentration in blood. Ital Heart J 2001;2:189-95.
7. Woodhouse PR, Khaw KT, Plummer M, Foley A, Meade TW. Seasonal variations of plasma fibrinogenand factor VII activity in the elderly: winter infections and death from cardiovascular disease. Lancet 1994;343:435-9.
8. Caswell M, Pike LA, Bull BS, Stuart J. Effect of patient age on tests of the acute-phase response. Arch Pathol Lab Med 1993;117:906-10.
9. Cook DG, Mendall MA, Whincup PH, Carey IM, Ballam L, Morris JE et al. C-reactive protein concentration in children: relationship to adiposity and other cardiovascular risk factors. Atherosclerosis 2000;149:139-50.
10. Calori G, Dangelo A, Dellavalle P, Ruotolo G, Ferini-Strambi L, Giusti C et al. The effect of cigarette-smoking on cardiovascular risk factors: a study of monozygotic twins discordant for smoking. Thromb Haemost 1996;75:14-8.
11. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol 1996;144:537-47.
12. Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction -a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19: 972-8.
13. Hak AE, Stehouwer CD, Bots ML, Polderman KH, Schalkwijk CG, Westendorp IC et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle aged women. Arterioscler Thromb Vasc Biol 1999;19:1986-91.
14. Mattush F, Dufaux B, Heine O, Mertens I, Rost R. Reduction of the plasma concentrations of C-reactive protein following nine months of endurance training. Int J Sports Med 2000;21:21-4.
15. Taafffe DR, Harris TB, Ferrucci L, Rowe J, Seeman TE. Cross-sectional and prospective relationship of interleukin-6 and C-reactive protein with physical performance in elderly persons: MacArthur studies of successful aging. J Gerontol A Biol Sci Med Sci 2000;55: M709-15.
16. Doggen CJM, Berckmans RJ, Sturk A, Cats VM, Rosendaal FR. C-reactive protein, cardiovascular risk factors, and the association with myocardial infarction in men. J Intern Med 2000;248:406-14.
17. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997;349:462-6.
18. Ganapathi MK, Mackiewicz A, Samols D, Brabenec A, Kushner I, Schultz D et al. Induction of C-reactive protein by cytokines in human hepatoma cell lines is potentiated by caffeine. Biochem J 1990;269:41-6.
19. Frolich M, Imhof A, Berg G, Boenig H, Brenner H, Koenig W. Congelation of C-reactive protein, a sensitive marker of the acute phase reaction with serum levels of various oxidants and antioxidants: results of a population-based study. Circulation 2000;102 Suppl:1075.
20. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healty middle-aged men -results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg cohort study, 1984 to 1992. Circulation 1999;99:237-42.
21. Bruno JJ. Inflammation, aspirin and the risk of cardiovascular disease. N Engl J Med 1997;337:422-4.
22. Connel EB, Connel JT. C-reactive protein in pregnancy and contraception. Am J Obstet Gynecol 1971;110: 633-9.
23. Kluft C. Pro-inflammatory effect of oestrogens. Fibrinolysis Proteolysis 1999;13:217-9.
24. Dangas G, Badimon JJ, Smith DA, Unger AH, Levine D, Shao JH et al. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol 1999;33:1294-304.
25. de Maat MPM, Kluft C, Hoogerbrugge N. No effect of pravastatin on C-reactive protein and fibrinogen levels. Fibrinolysis Proteolysis 1999; 13 Suppl 1:49-50.
26. Ridker PM, Rifai N, Pfeffer, Sacks F, Braunwald E. Long term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999;100:230-5.
27. Albert MA, Danielson E, Rifai N, Ridker PM; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64-70.
28. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998;98:839-44.
29. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM et al. Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-65.
30. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB et al. The prognostic value of C-reactive protein and serum amyloid A protein in severeunstable angina. N Engl J Med 1994;331:417-24.
31. Biasucci LM, Meo A, Buffon A, et al. Independent prognostic value of CRP levels for in-hospital death and myocardial infarction in unstable angina. Circulation 2000;102 Suppl:499.
32. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1998;31:1460-5.
33. Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Atery Disease. Circulation 1997;96:4204-10.
34. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med 2000;343:1139-47.
35. Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A et al. Elevated levels of C reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999;99:855-60.
36. Buffon A, Liuzzo G, Biasucci LM, Pasqualetti P, Ramazzotti V, Rebuzzi AG et al. Preprocedural serum levels of C reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999;34:1512-21.
37. Milazzo D, Biasucci LM, Luciani N, Martinelli L, Canosa C, Schiavello R et al. Elevated levels of C-reactive protein before coronary artery bypass grafting predict recurrence of ischemic events. Am J Cardiol 1999;84:459-61.
38. Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and troponinT in patient with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 antiplatelet therapy in unstable angina refractory to standard treatment trial. J Am Coll Cardiiol 2000;35:1535-42.
39. Pietila KO, Harmoinen AP, Jokiniitty J, Pasternack AI. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J 1996;17:1345-9.
40. Ridker PM. High-sensitive C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103:1813-8.
41. Mueller C, Buettner HJ, Hodgson JD, Marsch S, Perruchoud AP, Roskamm H et al. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation 2002;105: 1412-5.
42. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin-6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA 2001;286:2107-13.